Trial Profile
Open Label Phase II Study of MEN-10755 Administered Every 3 Weeks in Patients With Progressive Hormone Refractory Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sabarubicin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Feb 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 21 Nov 2007 New trial record.